Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys.

Oswald WB, Geisbert TW, Davis KJ, Geisbert JB, Sullivan NJ, Jahrling PB, Parren PW, Burton DR.

PLoS Pathog. 2007 Jan;3(1):e9.

2.
3.

Protective efficacy of neutralizing antibodies against Ebola virus infection.

Takada A, Ebihara H, Jones S, Feldmann H, Kawaoka Y.

Vaccine. 2007 Jan 22;25(6):993-9. Epub 2006 Oct 10.

PMID:
17055127
4.

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR.

J Virol. 2001 Sep;75(17):8340-7.

5.

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR.

PLoS Pathog. 2009 May;5(5):e1000433. doi: 10.1371/journal.ppat.1000433. Epub 2009 May 15.

6.
7.

Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever.

Marzi A, Yoshida R, Miyamoto H, Ishijima M, Suzuki Y, Higuchi M, Matsuyama Y, Igarashi M, Nakayama E, Kuroda M, Saijo M, Feldmann F, Brining D, Feldmann H, Takada A.

PLoS One. 2012;7(4):e36192. doi: 10.1371/journal.pone.0036192. Epub 2012 Apr 27.

8.

Passive immunization of rhesus macaques against SIV infection and disease.

Gardner M, Rosenthal A, Jennings M, Yee J, Antipa L, Robinson E Jr.

AIDS Res Hum Retroviruses. 1995 Jul;11(7):843-54.

PMID:
7546912
9.

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG.

Nat Med. 2000 Feb;6(2):207-10.

PMID:
10655111
10.

Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection.

Qiu X, Fernando L, Melito PL, Audet J, Feldmann H, Kobinger G, Alimonti JB, Jones SM.

PLoS Negl Trop Dis. 2012;6(3):e1575. doi: 10.1371/journal.pntd.0001575. Epub 2012 Mar 20.

11.

The emergence of antibody therapies for Ebola.

Hiatt A, Pauly M, Whaley K, Qiu X, Kobinger G, Zeitlin L.

Hum Antibodies. 2015 Dec 23;23(3-4):49-56. doi: 10.3233/HAB-150284. Review.

PMID:
27472862
12.

Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques.

Nakane T, Nomura T, Shi S, Nakamura M, Naruse TK, Kimura A, Matano T, Yamamoto H.

PLoS One. 2013 Sep 9;8(9):e73453. doi: 10.1371/journal.pone.0073453. eCollection 2013.

13.

Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail.

Kugelman JR, Kugelman-Tonos J, Ladner JT, Pettit J, Keeton CM, Nagle ER, Garcia KY, Froude JW, Kuehne AI, Kuhn JH, Bavari S, Zeitlin L, Dye JM, Olinger GG, Sanchez-Lockhart M, Palacios GF.

Cell Rep. 2015 Sep 29;12(12):2111-20. doi: 10.1016/j.celrep.2015.08.038. Epub 2015 Sep 10.

14.

Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates.

Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S400-3.

PMID:
17940976
15.

Glycoprotein-Specific Antibodies Produced by DNA Vaccination Protect Guinea Pigs from Lethal Argentine and Venezuelan Hemorrhagic Fever.

Golden JW, Maes P, Kwilas SA, Ballantyne J, Hooper JW.

J Virol. 2016 Jan 20;90(7):3515-29. doi: 10.1128/JVI.02969-15.

16.

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP.

Nature. 2014 Oct 2;514(7520):47-53. doi: 10.1038/nature13777. Epub 2014 Aug 29.

17.

Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 U.S. epizootic.

Jahrling PB, Geisbert TW, Jaax NK, Hanes MA, Ksiazek TG, Peters CJ.

Arch Virol Suppl. 1996;11:115-34.

PMID:
8800793
18.

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.

Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ.

Science. 2016 Mar 18;351(6279):1339-42. doi: 10.1126/science.aad5224. Epub 2016 Feb 25.

19.

Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP.

Reynard O, Volchkov VE.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S372-8. doi: 10.1093/infdis/jiv303. Epub 2015 Aug 1.

PMID:
26232760
20.

Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.

Mascola JR, Lewis MG, VanCott TC, Stiegler G, Katinger H, Seaman M, Beaudry K, Barouch DH, Korioth-Schmitz B, Krivulka G, Sambor A, Welcher B, Douek DC, Montefiori DC, Shiver JW, Poignard P, Burton DR, Letvin NL.

J Virol. 2003 Oct;77(19):10348-56.

Supplemental Content

Support Center